Bruno Diógenes Iepsen

Bruno Diógenes Iepsen

Auto-generated profile, based on publicly available information

Bruno Diógenes Iepsen

Hospital Geral de Fortaleza

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
ASAdalberto Studart-Neto
Adalberto Studart-Neto
BGBruno Fukelmann Guedes
Bruno Fukelmann Guedes
RTRaphael de Luca e Tuma
Raphael de Luca e Tuma
ACAntonio Edvan Camelo-Filho
Antonio Edvan Camelo-Filho
GKGabriel Taricani Kubota
Gabriel Taricani Kubota
RNRicardo Nitrini
Ricardo Nitrini
Background: More than one-third of COVID-19 patients present neurological symptoms ranging from anosmia to stroke and encephalopathy. Furthermore, pre-existing neurological conditions may require special treatment and may be associated with worse outcomes. Notwithstanding, the role of neurologists in COVID-19 is probably underrecognized. Objective: The aim of this study was to report the reasons for requesting neurological consultations by internists and intensivists in a COVID-19-dedicated hospital. Methods: This retrospective study was carried out at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil, a 900-bed COVID-19 dedicated center (including 300 intensive care unit beds). COVID-19 diagnosis was confirmed by SARS-CoV-2-RT-PCR in nasal swabs. All inpatient neurology consultations between March 23rd and May 23rd, 2020 were analyzed. Neurologists performed the neurological exam, assessed all available data to diagnose the neurological condition, and requested additional tests deemed necessary. Difficult diagnoses were established in consensus meetings. After diagnosis, neurologists were involved in the treatment. Results: Neurological consultations were requested for 89 out of 1,208 (7.4%) inpatient COVID admissions during that period. Main neurological diagnoses included: encephalopathy (44.4%), stroke (16.7%), previous neurological diseases (9.0%), seizures (9.0%), neuromuscular disorders (5.6%), other acute brain lesions (3.4%), and other mild nonspecific symptoms (11.2%). Conclusions: Most neurological consultations in a COVID-19-dedicated hospital were requested for severe conditions that could have an impact on the outcome. First-line doctors should be able to recognize neurological symptoms; neurologists are important members of the medical team in COVID-19 hospital care.

7 January 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
RTRaphael L. Tuma
Raphael L. Tuma
BGBruno Fukelmann Guedes
Bruno Fukelmann Guedes
RCRafael Bernhart Carra
Rafael Bernhart Carra
BIBruno Iepsen
Bruno Iepsen
JRJúlia Rodrigues
Júlia Rodrigues
LCLuiz H. Castro
Luiz H. Castro

1 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RTRaphael Tuma
Raphael Tuma
BGBruno Fukelmann Guedes
Bruno Fukelmann Guedes
RCRafael Bernhart Carra
Rafael Bernhart Carra
BIBruno Iepsen
Bruno Iepsen
JRJúlia Rodrigues
Júlia Rodrigues
LCLuiz Henrique Castro
Luiz Henrique Castro
Objective: To describe the clinical, neurological, neuroimaging and cerebrospinal fluid (CSF) findings associated with encephalopathy in patients admitted to a COVID-19 tertiary reference center. Methods: We retrospectively reviewed records of consecutive patients with COVID-19 evaluated by a consulting neurology team from March 30, 2020 through May 15, 2020. Results: Fifty-five patients with confirmed SARS-CoV-2 were included, 43 of whom showed encephalopathy, and were further divided into mild, moderate and severe encephalopathy groups. Nineteen patients (44%) had undergone mechanical ventilation and received intravenous sedatives. Eleven (26%) patients were on dialysis. Laboratory markers of COVID-19 severity were very common in encephalopathy patients, but did not correlate with the severity of encephalopathy. Thirty-nine patients underwent neuroimaging studies, which showed mostly non-specific changes. One patient showed lesions possibly related to CNS demyelination. Four had suffered an acute stroke. SARS-CoV-2 was detected by RT-PCR in only one of 21 CSF samples. Two CSF samples showed elevated white blood cell count and all were negative for oligoclonal bands. In our case series the severity of encephalopathy correlated with higher probability of death during hospitalization (OR = 5.5 for each increment in the degree of encephalopathy, from absent (0) to mild (1), moderate (2) or severe (3), p<0.001). Conclusion: In our consecutive series with 43 encephalopathy cases, neuroimaging and CSF analysis did not support the role of direct viral CNS invasion or CNS inflammation as the cause of encephalopathy.

2 January 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BGBruno Fukelmann Guedes
Bruno Fukelmann Guedes
ARAna Ritto
Ana Ritto
ASAndre Macedo Serafim Silva
Andre Macedo Serafim Silva
ACAntonio Edvan Camelo-Filho
Antonio Edvan Camelo-Filho
CMCristiane de Araújo Martins Moreno
Cristiane de Araújo Martins Moreno
LCLuiz Henrique Martins Castro
Luiz Henrique Martins Castro
Somatic neurological complications are an underexplored component of post-acute sequelae of SARS-CoV-2 infection. We evaluated long-term somatic neurological symptoms, examination findings, and suspected diagnoses among adults hospitalized for COVID-19. A total of 708 survivors were assessed 6–11 months after discharge using a structured three-step neurological evaluation based on the World Health Organization Protocol for Epidemiologic Studies of Neurologic Disorders : an adapted symptom questionnaire, a brief standardized neurological examination, and a full neurological consult. Muscle weakness, gait impairment, and paresthesias remained the most frequent symptoms at follow-up. Longer hospital stay predicted all three symptoms, and diabetes was associated with both gait impairment and paresthesias. Common examination findings included monoparesis, hemiparesis, and gradient-pattern sensory loss. Clinically suspected diagnoses included neuromuscular disease in 26%, cerebrovascular disease in 10%, and epilepsy in only 2.7% of cases. Logistic regression linked neuromuscular disease to paresthesias and tandem-walk failure, cerebrovascular disease to facial paralysis, and epilepsy to loss-of-contact episodes. A simplified screening model derived through best-subsets selection identified five informative items from the WHO protocol: paresthesias, facial paralysis, tandem walk, index–nose test, and loss-of-contact episodes. These findings indicate that somatic neurological abnormalities remain frequent months after severe COVID-19 and that a brief bedside subset may support efficient post-COVID neurological triage.

15 July 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
AVAna Silvia Sobreira Lima Verde
Ana Silvia Sobreira Lima Verde
AMAlessandra Braga Cruz Guedes de Morais
Alessandra Braga Cruz Guedes de Morais
ACAmanda Vale Catunda
Amanda Vale Catunda
JLJoão Igor Dantas Landim
João Igor Dantas Landim
IRIan Silva Ribeiro
Ian Silva Ribeiro
NFNorberto Anízio Ferreira Frota
Norberto Anízio Ferreira Frota
Cerebral amyloid angiopathy (CAA) is a small vessel disease characterized by the deposition of amyloid-beta in small cerebral vessels, which can lead to intracerebral hemorrhages and cognitive impairment. Rare variants, such as cerebral amyloid angiopathy-related inflammation (CAA-ri) and iatrogenic CAA (ICAA), may mimic other neurological conditions and challenge diagnosis in clinical practice. We present three cases that illustrate distinct CAA syndromes, along with CSF biomarker analysis. One patient experienced recurrent hemorrhagic strokes with a history of dural graft, raising concerns about amyloid transmission. Two patients presented with rapidly progressive dementia that fulfilled CAA-ri criteria. All cases exhibited decreased levels of CSF Aβ40 and Aβ42, with one showing elevated p-tau, suggesting comorbid Alzheimer's pathology. Cerebrospinal fluid biomarkers complement neuroimaging in the diagnosis of CAA, aiding in differentiation from other dementias. Early recognition and diagnosis of CAA-ri variants is crucial, because immunotherapy may improve outcomes. Further research is necessary to establish biomarker thresholds and their clinical applicability.

22 October 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
CBCaio Viana Botelho
Caio Viana Botelho
ACAmandha Carneiro
Amandha Carneiro
CRCarolina Regadas
Carolina Regadas
CCCintia Cavalcante
Cintia Cavalcante
IRIan Ribeiro
Ian Ribeiro
NFNorberto Anizio Ferreira Frota
Norberto Anizio Ferreira Frota
Background: Alzheimer's disease (AD) has evolved from a syndromic diagnosis to a biologically defined entity supported by cerebrospinal fluid (CSF) biomarkers. The Alzheimer's Association 2024 (AA-2024) criteria are expected to expand biological AD classification compared with the 2018 NIA–AA AT(N) framework. Objective: To compare biological AD classification using the AT(N) 2018 framework and the AA-2024 criteria in a real-world cohort. Methods: We conducted a retrospective study including 146 consecutive patients evaluated for cognitive impairment in a tertiary neurology center who underwent CSF biomarker testing (Aβ 42 , Aβ 40 , Aβ 42 /Aβ 40 ratio, phosphorylated tau, and total tau). Each patient was classified according to AT(N) 2018 and AA-2024 criteria. Diagnostic distributions, reclassification patterns, and agreement (Cohen's κ) were analyzed. Group comparisons used Wilcoxon rank-sum and Fisher's exact tests. Results: Under AT(N) 2018, 40/146 (27.4%) patients met biological AD criteria, whereas AA-2024 classified 72/146 (49.3%) as AD. Reclassification occurred exclusively from non-AD to AD (32 patients, 21.9%), with no reverse reclassification. Agreement was moderate (κ = 0.57). Concordant AD cases (AD+/AD+) showed lower Aβ 42 /Aβ 40 ratios and higher total and phosphorylated tau levels than reclassified cases (AD−/AD+) (all p < 0.001), as well as higher neurodegeneration marker positivity (70% versus 25%; p < 0.001). Final clinical AD diagnosis was assigned to 98% of concordant cases versus 38% of reclassified cases (p < 0.001). Conclusions: AA-2024 increases biological AD classification by identifying amyloid-positive individuals with lower tau burden and clinical heterogeneity, underscoring the need to integrate biomarker-based definitions with clinical and longitudinal assessment.